Immunicum Receive Extended SME-Status From the European Medicines Agency

Published: Jun 18, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Gothenburg, 2013-06-18 10:50 CEST (GLOBE NEWSWIRE) -- Immunicum AB (publ), a Swedish listed company developing therapeutic cancer vaccines, today received prolonged SME-status from the European Medicines Agency. The status is extended one year with the possibility of further extension and means significantly lower fees and faster handling on cases involving EMA. The purpose of EMA’s SME department is to actively promote the innovation and development of drugs in small and medium size enterprises.

Help employers find you! Check out all the jobs and post your resume.

Back to news